$BPTH
BIO-PATH HOLDINGS, INC.

2024 Q1 Form 10-K Financial Statement

#000155837024002730 Filed on March 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.407M $757.0K $4.235M
YoY Change 7.98% -32.59% -10.58%
% of Gross Profit
Research & Development $2.288M $2.276M $11.61M
YoY Change -42.64% -20.5% 26.66%
% of Gross Profit
Depreciation & Amortization $22.00K $16.00K $82.00K
YoY Change 0.0% -30.43% -18.0%
% of Gross Profit
Operating Expenses $3.695M $3.033M $15.84M
YoY Change -30.18% -23.91% 13.97%
Operating Profit -$3.695M -$15.84M
YoY Change -30.18% 13.97%
Interest Expense $0.00 $4.000K $36.00K
YoY Change -100.0% -80.0% 9.09%
% of Operating Profit
Other Income/Expense, Net $538.0K -$343.0K -$271.0K
YoY Change 2731.58% -921.21%
Pretax Income -$3.157M -$3.372M -$16.08M
YoY Change -40.13% -14.98% 15.94%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.157M -$3.372M -$16.08M
YoY Change -40.13% -14.98% 15.67%
Net Earnings / Revenue
Basic Earnings Per Share -$4.88 -$33.63
Diluted Earnings Per Share -$4.88 -$5.51 -$33.64
COMMON SHARES
Basic Shares Outstanding 678.8K 12.35M 478.0K
Diluted Shares Outstanding 647.0K 478.0K

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $188.0K $1.052M $1.052M
YoY Change -97.21% -89.87% -89.87%
Cash & Equivalents $188.0K $1.052M
Short-Term Investments
Other Short-Term Assets $800.0K $1.990M $1.990M
YoY Change -51.92% 21.05% -61.96%
Inventory
Prepaid Expenses $632.0K $632.0K
Receivables
Other Receivables
Total Short-Term Assets $1.637M $3.042M $3.042M
YoY Change -84.83% -80.52% -80.52%
LONG-TERM ASSETS
Property, Plant & Equipment $54.00K $178.0K $178.0K
YoY Change -60.29% 12.66% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $131.0K $178.0K $178.0K
YoY Change -57.88% -50.0% -50.0%
TOTAL ASSETS
Total Short-Term Assets $1.637M $3.042M $3.042M
Total Long-Term Assets $131.0K $178.0K $178.0K
Total Assets $1.768M $3.220M $3.220M
YoY Change -84.07% -79.84% -79.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.700M $57.00K $57.00K
YoY Change 105.56% -91.45% -272.73%
Accrued Expenses $2.000M $1.449M $1.449M
YoY Change 105.55% 61.0% 42.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.812M $1.906M $1.906M
YoY Change 99.58% 13.18% 13.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $581.0K $873.0K $873.0K
YoY Change 583.53% 672.57% 672.57%
Total Long-Term Liabilities $581.0K $873.0K $873.0K
YoY Change 583.53% 672.57% 672.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.812M $1.906M $1.906M
Total Long-Term Liabilities $581.0K $873.0K $873.0K
Total Liabilities $4.393M $2.779M $2.779M
YoY Change 120.2% 54.65% 54.65%
SHAREHOLDERS EQUITY
Retained Earnings -$110.8M -$107.6M
YoY Change 14.42% 17.6%
Common Stock $1.000K $1.000K
YoY Change -87.5% -87.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.600M $441.0K $441.0K
YoY Change
Total Liabilities & Shareholders Equity $1.768M $3.220M $3.220M
YoY Change -84.07% -79.84% -79.84%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$3.157M -$3.372M -$16.08M
YoY Change -40.13% -14.98% 15.67%
Depreciation, Depletion And Amortization $22.00K $16.00K $82.00K
YoY Change 0.0% -30.43% -18.0%
Cash From Operating Activities -$1.038M -$1.814M -$11.54M
YoY Change -71.58% -63.72% -23.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.203M
YoY Change 27.05%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 174.0K 514.0K 2.203M
YoY Change -70.36% 27.05%
NET CHANGE
Cash From Operating Activities -1.038M -1.814M -11.54M
Cash From Investing Activities
Cash From Financing Activities 174.0K 514.0K 2.203M
Net Change In Cash -864.0K -1.300M -9.332M
YoY Change -76.35% -60.2% -30.31%
FREE CASH FLOW
Cash From Operating Activities -$1.038M -$1.814M -$11.54M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
478000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
364000
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
398000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
618000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-33.63
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-38.12
CY2022 us-gaap Depreciation
Depreciation
100000
CY2023 bpth Term Commitments Are Incurred
TermCommitmentsAreIncurred
P12M
CY2023 us-gaap Operating Loss Carryforwards Expiration Date
OperatingLossCarryforwardsExpirationDate
2037-12-31
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36333
CY2023 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
CY2023 dei City Area Code
CityAreaCode
832
CY2023 dei Local Phone Number
LocalPhoneNumber
742-1357
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
BPTH
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
678795
CY2023Q2 dei Entity Public Float
EntityPublicFloat
13509998.86
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young
CY2023 dei Auditor Location
AuditorLocation
Houston, Texas
CY2023Q4 us-gaap Cash
Cash
1052000
CY2022Q4 us-gaap Cash
Cash
10384000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
632000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3587000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1358000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1644000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3042000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
15615000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1044000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
962000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
158000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
102000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2023Q4 us-gaap Assets
Assets
3220000
CY2022Q4 us-gaap Assets
Assets
15971000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
457000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
667000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1346000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1906000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1684000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2023Q4 us-gaap Liabilities
Liabilities
2779000
CY2022Q4 us-gaap Liabilities
Liabilities
1797000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
618000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
398000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
108047000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105702000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107607000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91529000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
441000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14174000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3220000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15971000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11608000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9165000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4235000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4736000
CY2023 us-gaap Operating Expenses
OperatingExpenses
15843000
CY2022 us-gaap Operating Expenses
OperatingExpenses
13901000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-15843000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-13901000
CY2023 bpth Period Changes In Fair Value Of Warrant Liability
PeriodChangesInFairValueOfWarrantLiability
271000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
36000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-235000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16078000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13868000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-33.63
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-38.12
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
478000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
364000
CY2023 us-gaap Profit Loss
ProfitLoss
-16078000
CY2022 us-gaap Profit Loss
ProfitLoss
-13868000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
734000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
851000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
96000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
90000
CY2023 us-gaap Depreciation
Depreciation
82000
CY2022 us-gaap Depreciation
Depreciation
88000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
271000
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2955000
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
3064000
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-286000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-199000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
227000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
700000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-108000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-99000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11535000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15103000
CY2022 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
21000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1677000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1734000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
526000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2203000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1734000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9332000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13390000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1052000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10384000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
25457000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1734000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
851000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13868000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14174000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14174000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
491000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1120000
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
734000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16078000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
441000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk — </span>Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash. The Company maintains its cash balances with one major commercial bank, JPMorgan Chase Bank. The balances are insured by the Federal Deposit Insurance Corporation (the “FDIC”) up to $250,000. As a result, as of December 31, 2023, approximately $0.8 million of its cash balance was not covered by the FDIC. As of December 31, 2022, the Company had </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approximately $10.4 million in cash on-hand, of which approximately $10.1 million was not covered by the FDIC. To date, the Company has not incurred any losses on its cash balances.</p>
CY2023 us-gaap Depreciation
Depreciation
100000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates —</span> The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States (“U.S.”) requires management to make estimates and assumptions that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends as well as on various other assumptions that the Company believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from the Company’s estimates. These estimates include prepaid and accrued clinical trial costs, stock-based compensation expense, valuation of warrants and valuation of deferred tax assets.</p>
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-16100000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-13900000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107600000
CY2023Q4 us-gaap Cash
Cash
1100000
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1400000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1600000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1044000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
962000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
158000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
500000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
700000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
863000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
115000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.80
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
74.20
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0342
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0243
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.29
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.27
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
291.60
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7800000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
10000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
74.20
CY2022 bpth Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodContractualTerm
P9Y3M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
119.20
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
33000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
233.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
32000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
238.00
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
16000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
372.40
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3M18D
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
700000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
900000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y9M18D
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
900000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
190000
CY2023 bpth Class Of Warrant Or Right Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightWeightedAverageRemainingContractualLife
P4Y1M6D
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
190000
CY2023Q4 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
900000
CY2023 bpth Operating Lease Incremental Borrowing Rate Utilized
OperatingLeaseIncrementalBorrowingRateUtilized
0.080
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
102000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
103000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
108000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
113000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
113000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
221000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
113000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
10000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
5000
CY2023 us-gaap Lease Cost
LeaseCost
123000
CY2022 us-gaap Lease Cost
LeaseCost
120000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
108000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
11000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
119000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
113000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2023 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Match First3 Of Base Salary
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchFirst3OfBaseSalary
1
CY2023 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Tranche One
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayTrancheOne
0.03
CY2023 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Match On Next2 Of Base Salary
DefinedContributionPlanEmployerMatchingContributionPercentOfMatchOnNext2OfBaseSalary
0.50
CY2023 bpth Defined Contribution Plan Employer Matching Contribution Percent Of Employees Gross Pay Tranche Two
DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayTrancheTwo
0.02
CY2023Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
52000
CY2022Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
37000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
97300000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
35800000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
61500000
CY2023 bpth Net Operating Loss Tax Basis
NetOperatingLossTaxBasis
88300000
CY2023 bpth Tax Credits Earned After2019
TaxCreditsEarnedAfter2019
4800000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5000000.0
CY2023 bpth Valuation Allowance As Percent Of Deferred Tax Assets
ValuationAllowanceAsPercentOfDeferredTaxAssets
1
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24200000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19100000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
22000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
63000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
24000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Other
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
28000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18550000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15818000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4769000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2509000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
750000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
671000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
24000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
46000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
50000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
44000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24192000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19182000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24171000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19140000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
21000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
42000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
21000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
42000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16078000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13868000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3376000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2912000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
74000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
80000
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2261000
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-844000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5031000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
98000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
57000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0
CY2023 us-gaap Income Tax Reconciliation Tax Contingencies Other
IncomeTaxReconciliationTaxContingenciesOther
0
CY2022 us-gaap Income Tax Reconciliation Tax Contingencies Other
IncomeTaxReconciliationTaxContingenciesOther
1890000
CY2023 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
475000
CY2022 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001558370-24-002730-index-headers.html Edgar Link pending
0001558370-24-002730-index.html Edgar Link pending
0001558370-24-002730.txt Edgar Link pending
0001558370-24-002730-xbrl.zip Edgar Link pending
bpth-20231231.xsd Edgar Link pending
bpth-20231231x10k.htm Edgar Link pending
bpth-20231231x10k001.jpg Edgar Link pending
bpth-20231231x10k002.jpg Edgar Link pending
bpth-20231231x10k003.jpg Edgar Link pending
bpth-20231231x10k004.jpg Edgar Link pending
bpth-20231231x10k005.jpg Edgar Link pending
bpth-20231231x10k006.jpg Edgar Link pending
bpth-20231231x10k007.jpg Edgar Link pending
bpth-20231231x10k008.jpg Edgar Link pending
bpth-20231231x10k009.jpg Edgar Link pending
bpth-20231231xex23d1.htm Edgar Link pending
bpth-20231231xex31.htm Edgar Link pending
bpth-20231231xex32.htm Edgar Link pending
bpth-20231231xex97.htm Edgar Link pending
bpth-20231231_cal.xml Edgar Link unprocessable
bpth-20231231x10k_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bpth-20231231_def.xml Edgar Link unprocessable
bpth-20231231_pre.xml Edgar Link unprocessable
bpth-20231231_lab.xml Edgar Link unprocessable